This study aimed to evaluate the effect of sirolimus (SRL; rapamycin) as an immunosuppressant during xenotransplantation (XT) of rabbit hepatocytes into male Wistar rats with acute liver failure (ALF; n = 72). Isolated rabbit hepatocytes were transplanted intrasplenically into rats within 24 h of chemically induced ALF. Treatment groups received monotherapy with either cyclosporine (CsA) 20 mg/kg or SRL 0.20 mg/kg, or combination therapy with CsA 20 mg/kg + SRL 0.20 mg/kg for 14 days post-transplant. One control group with ALF received no treatment and a second group with ALF received only XT. Surviving rats were euthanized after 14 days, with concurrent blood sampling and organ retrieval for morphological evaluation. Survival rates at 14 days were: no XT/no treatment, 0%; XT alone, 29%; XT + CsA, 79%; XT + SRL, 33%; and XT + CsA + SRL, 33%. Liver morphology showed statistically superior liver regeneration for groups on SRL therapy. It is concluded that, in this hepatocyte XT model, SRL offered no survival advantage for ALF management so CsA still maintains a central role in attempts to develop alternative solutions for ALF.
Introduction
Acute liver failure (ALF) is a demanding clinical entity carrying an extremely poor prognosis that ends in death in 80% of cases if left untreated. Although orthotopic liver transplantation is considered as the treatment of choice, the existing donor shortage restricts the opportunity for transplantation to only one-third of potential recipients. 1 -3 In recent years, cellular liver replacement methods have been developed as bridging therapies to transplantation. Xenotransplantation (XT) of hepatocytes represents an alternative in vivo method of tissue engineering that overcomes the difficulties of bio-artificial liver devices, but has limitations in its application; the major limitation being the need for an immunosuppressive regimen. 4 -6 Since cyclosporine had the first clinical D Lytras, A Papalois, AK Tsaroucha et al. Experimental xenotransplantation of hepatocytes success in a liver transplant patient, 7 its ability to improve survival has been shown in a number of studies. 8 In the present study, the impact of cyclosporine A (CsA) in combination with sirolimus (SRL; rapamycin, Rapamune ® ) on survival was evaluated. SRL is a macrolide with immunosuppressive properties. It inhibits the response to interleukin-2, thereby blocking activation of T-and B-cells. The mode of action of SRL is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in a manner similar to tacrolimus. Unlike the tacrolimus-FKBP12 complex, which inhibits calcineurin (PP2B), the SRL-FKBP12 complex inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR complex 1 (mTORC1). 9 In the literature, it is well established that the introduction of SRL in immunosuppressive regimens has reduced the incidence of acute graft rejections. 10 -12 To the best of the authors' knowledge, there are no reports regarding the efficacy of the drug in the field of hepatocyte XT. The aim of the present study was to evaluate the efficacy of SRL as an immunosuppressive regimen in a rabbit to rat model of hepatocyte XT after chemical induction of ALF. This study adds to the body of knowledge on the possible future use of hepatocytes from other mammals (e.g. swine) in human XT after ALF, under an immunosuppressive regimen, as a bridging therapy prior to liver transplantation.
Materials and methods

ANIMALS
One male New Zealand rabbit, weighing 2600 g, was used as a donor of fresh hepatocytes. Wistar rats (n = 72), weighing 220 -400 g, were used as hepatocyte recipients. All animals were obtained from the Pasteur Institute, Athens, Greece. The donor rabbit was maintained in a central animal facility and received water and nutrition ad libitum. All rats were maintained on standard laboratory rat food under a 12 h light/12 h dark cycle. All procedures were carried out within the European Union guidelines for the humane care of laboratory animals and Greek legislation (Act 160, Vol 64, No. A, May 1991). The study was approved by the Scientific Committee of the Democritus University of Thrace and the Veterinary Authorities of East Attica-Athens.
INDUCTION OF ALF
Induction of ALF was carried out using 18 mg/kg of N-nitrosodimethylamine (NDMA; N3632; Sigma-Aldrich, St Louis, MO, USA) given as an intravenous bolus injection. If left untreated, injection of NDMA causes acute hepatic necrosis with a fatal outcome within 72 h. 13, 14 All rats remained under surveillance for the 24 h after NDMA injection with ad libitum access to food and water.
XENOTRANSPLANTATION PROCEDURE
Temporary anaesthesia was induced in recipient rats by intramuscular injection of 0.5 ml solution of 100 mg/ml ketamine hydrochloride (Narketan ® 10; Vétoquinol, Great Slade, UK), xylazine (Xylaject 2%; Dopharma BV, Raamsdonksveer, The Netherlands) and NaCl 0.9%, in the ratio of 1:1:2.
Fresh rabbit hepatocytes were isolated according to the method proposed by Papalois et al. 15 The donor rabbit liver was heparinized with 5000 IU for 5 min and then euthanasia of the donor was performed. Following transection of the suprahepatic inferior vena cava, in order to remove all the cellular components of the hepatic vascular network, the liver was perfused with 1 l of cold Ringer's solution (Baxter, Deerfield, IL, D Lytras, A Papalois, AK Tsaroucha et al.
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USA) at a rate of 20 ml/min. The liver was then placed in a sterile chamber component of a cyclic perfusion conduit, and collagenase type V solution (1.3 mg/ml) (C9263; Sigma-Aldrich) along with Hank's balanced salt solution 10× (Biological Industries, Kibbutz Beit Haemek, Israel) and newborn calf serum 5% (N4637; Sigma-Aldrich) were perfused for 5 min. In order to maintain collagenase activity, the liver was incubated for 40 min in a water bath at a steady temperature of 37 ºC. After 'digestion', the frail parenchyma was placed in Hank's balanced salt solution (450 ml H 2 O, 50 ml Hank's balanced salt solution 7.5%, 2.5 ml penicillin/streptomycin, 46 ml newborn calf serum) at 4 ºC for inhibition of collagenase. Filtration through a 400-µm metal sieve was then carried out to remove the nonparenchyma structures. The filtered hepatocytes were collected in 5% Hank's balanced salt solution and two consecutive centrifugations were performed for 12 min at 300 g. Viability of the hepatocytes was measured by the trypan blue exclusion test (Serva, Heidelberg, Germany).
After general anaesthesia each rat recipient underwent a median laparotomy and the spleen was exposed. Freshly isolated hepatocytes in a volume of 0.70 ml (10 8 viable hepatocytes) were injected into the inferior splenic lobe using a 25-gauge needle connected to a 1 ml syringe, and a silk 3/0 suture ligation was then placed proximally to the injection site in order to avoid hepatocyte leakage and haemorrhage.
TREATMENTS
Following transplantation and abdominal closure, the recipients were randomized to the following treatment groups: (i) ALF + XT (n = 14); (ii) ALF + XT + CsA monotherapy (20 mg/kg) (n = 19); (iii) ALF + XT + SRL monotherapy (0.20 mg/kg) (n = 12); and (iv) ALF + XT + CsA + SRL (20 mg/kg and 0.20 mg/kg, respectively) (n = 12). All treatments were given orally every day for 14 days. One group of rats with untreated ALF (i.e. no treatment and no XT) was used as a control group (n = 15). This control group underwent euthanasia at 24 h and the extent of liver damage was evaluated by histopathology and standard laboratory tests (lactate dehydrogenase, glucose, serum glutamic pyruvic transaminase, serum glutamic oxaloacetic transaminase, creatinine, K + and Na + levels). Survival data from a second control group, which was shared in common with a concurrent experimental protocol that was carried out in the laboratory and has been reported elsewhere, were also included. 16 This group of rats (n = 13) also had untreated ALF without XT and they were included in the present study to evaluate the survival rate in this group.
Only animals that survived immediately after the injection of NDMA were included in the analyses. The end point of the study was survival up to day 14 after the induction of ALF, based on the procedures set in previous XT studies. 16, 17 A short study period of 14 days was chosen in order to evaluate the capability of transplanted hepatocytes, under an immunosuppressive regimen, to support liver function as a bridging therapy prior to liver transplantation. At 14 days all animals that had survived underwent euthanasia, followed by autopsy in order to evaluate their histology. All biochemical parameters that were measured were obtained from blood samples taken prior to euthanasia on day 14.
The pathological evaluation was performed by two pathologists (N.G. and M.L.) who were blinded to the different treatment groups. Evaluation of morphology was performed according to the modified Histological Activity Index (HAI) grading of D Lytras, A Papalois, AK Tsaroucha et al.
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Ishak et al. 18 Since there is no proposed histopathological nomenclature for acute liver damage, semi-quantitative estimation of parameters, such as confluent necrosis, focal lytic necrosis and apoptosis with liver cell drop-out, was used for determination of liver damage (Table 1 ).
STATISTICAL ANALYSIS
All statistical analyses were carried out using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . For comparison of the qualitative parameters among the treatment groups the Kruskal-Wallis and Mann-Whitney U-test methods were used. Survival was analysed using the Kaplan-Meier analysis. A P-value < 0.05 was considered to be statistically significant.
Results
The mean ± SD viability of the collected rabbit hepatocytes was 92% ± 6% and contamination of non-parenchymal cell was < 2%. Statistically significant differences were observed among groups regarding the biochemical parameters of creatinine, K + , Na + , glucose, serum glutamic pyruvic transaminase, serum glutamic oxaloacetic acid and total bilirubin levels (P < 0.05). As expected, all surviving animals showed improvement of liver function compared with the control group with untreated ALF ( Table 2 ). All the animals with untreated ALF from the second control group died during the first 3 days after NDMA-induced ALF. Only 4/14 animals survived to day 14 in the group treated with XT alone, a survival rate of 29%. The survival rate for the CsA monotherapy group was 79% (15/19 animals) and this was statistically significantly higher than the survival rate of 33% (4/12 animals) demonstrated in both the SRL monotherapy (P = 0.008) and CsA + SRL combination therapy (P = 0.005) groups (Fig. 1A) . A statistically significant difference in terms of survival rate was demonstrated between all study groups (log rank = 25.99, P = 0.0037, Kruskal-Wallis test). 
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Liver specimens from surviving animals were collected from the ALF group at 24 h and from the other groups on day 14. All specimens underwent histopathological evaluation by the same two pathologists and were scored according to the aforementioned modified HAI severity scale (Table 3) . Overall, a statistically significant difference in the HAI score was demonstrated between study groups and the control (P < 0.05), with the untreated ALF control group demonstrating the highest values due to 1  2  3  5  2  2  0  2  3  2  1  3  4  2  0  2  5  2  1  3  6  3  2  5  7  1  1  2  8  0  2  2  9  2  1  3  1 0  2  0  2  1 1  2  1  3  1 2  0  2  2  1 3  0  2  2  1 4  1  1  2  1 5  2  0  2  XT + SRL  1  0  0  0  2  2  0  2  3  0  1  1  4  1  2  3  XT + SRL + CSA  1  0  1  1  2  3  2  5  3  3  0  3  4  0  1  1 a Liver histology was scored according to the modified Histological Activity Index (HAI) grading system of Ishak et al. 18 with the scoring system shown in Table 1 
extensive panacinar necrosis as expected (Fig. 1B) .
The main morphological feature in the CsA monotherapy group was characterized by hepatic nodular-like regeneration ( Fig.  2A) . In animals that underwent SRL monotherapy, focal regenerative nodules consisting of hyperplastic hepatocytes arranged in two-cell-thick plates between delicate septa of fibrous tissue were observed (Fig. 2B) . In animals that underwent SRL + CsA combination therapy, adequate liver regeneration was observed. Although the mean severity score of histopathological findings in the SRL monotherapy group demonstrated an advantageous morphology profile (mean score 1.50 for the SRL group versus 2.67 for the CsA group and versus 2.50 for the SRL + CsA group) these findings did not reach statistical significance. Two animals in the SRL monotherapy group demonstrated evidence of tubular and glomerular necrosis in the histopathological examination, whilst analysis of only one rat in the SRL + CsA group revealed similar findings.
Discussion
The results of the present study clearly indicate that SRL, given either as monotherapy or in combination therapy with CsA, does not offer a survival advantage when compared with CsA monotherapy on the basis of success of hepatocyte XT for ALF.
Makowka et al. 19 reported that allogeneic and xenogeneic hepatocyte transplantation in experimental hepatic failure can be a potentially safe and efficacious procedure, despite sensitization and the absence of any immunosuppressive treatment. Makowka et al. 20 also reported the reversal of toxic-and anoxic-induced hepatic failure by syngeneic, allogeneic and xenogeneic hepatocyte transplantation, again without the use of any immunosuppressive drug.
A significant body of work exists in the literature regarding the study of ALF in experimental animal models and a variety of agents, either mechanical or chemical, have been used in an effort to approach the clinical presentation of the disease at the human level. 20 -26 The majority of these models refer, however, either to progressively established, chemically induced ALF or to hepatocyte XT prior to the establishment of ALF. In contrast to these models, the present study used a drug-induced model of ALF by administration of NDMA, an agent that results in rapid central acinar haemorrhagic necrosis and is associated with a fatal outcome if left untreated. Furthermore, this model of ALF does not allow for potential self-recovery of the liver, other than by transplantation, which reflects the real conditions and dilemmas that are associated with the clinical entity of ALF. This poor outcome was clearly demonstrated in the second control group with untreated ALF, for which the survival rate was 0% after 14 days, with all deaths occurring within 3 days following induction of ALF with NDMA. 16 A statistically superior advantage was observed with CsA monotherapy, with a survival rate (79%) that was more than twice that demonstrated by both the groups that received SRL (33% survival for each group). One possible explanation for this could be inadequate engraftment of rabbit hepatocytes or primary post-transplant non-function failure, since the majority of deaths occurred between the second and the fourth day after XT. Hepatocyte migration to the liver, which would have provided evidence of an immune response at sites of rabbit hepatocyte localization, was not tracked in the present study. Gupta et al. 27 reported, however, that hepatocytes of intrasplenic transplantation D Lytras, A Papalois, AK Tsaroucha et al. In combination with the laboratory and histopathology findings, it could be argued that there are other possible explanations for the outcomes observed in the present study. Andoh and Bennett 28 reported that SRL administration is associated with excessive osmotic diuresis due to hyperglycaemia, which leads to renal impairment; a finding that is in agreement with observations made in the SRL monotherapy group in the present study, where statistically significantly higher values of blood glucose and serum K + were observed.
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Regarding the survival rate of animals that received combination therapy with SRL + CsA, the possibility of nephrotoxic interactions between the agents of the regimen cannot be excluded. 29, 30 In the present study, renal impairment was observed in only two survivors that received SRL and one survivor that received SRL + CsA, as demonstrated by tubular and glomerular nephropathy at histological examination. As this was not explored further using nephrotoxic doses of SRL, it is not possible to reach a conclusion regarding the nephrotoxicity of SRL. A more plausible explanation was that CsA prevented or delayed rejection of the injected hepatocytes sufficiently to allow survival of the rat and regeneration of the native liver. 8 The combination of SRL + CsA would, therefore, be expected to improve the outcome; however, this was not the case in the present study. As previously reported, SRL prevents tumour cell replication, and also inhibits p70 S6 kinase activation and liver regeneration, but not functional phosphorylation of eukaryotic translation initiation factor 4Ebinding protein 1 (4E-BP1), in response to partial hepatectomy. 9, 31 Thus, SRL inhibits liver regeneration, but probably only during the proliferation phase of hepatic cells. 32 A recent study has indicated that SRL has a significant impact on neoangiogenesis and can attenuate fibrosis and cirrhosis. 32 Evaluation of morphology in liver tissues was performed using the modified semiquantitative method according to Ishak et al. 18 Although this scoring system is widely accepted for grading and staging of chronic hepatitis, we believe that, by selecting the components for estimation of confluent and focal necrosis, we can objectively approach the severity of distortion in the hepatic parenchyma in this model of NDMAinduced rapid liver failure.
Hepatic morphology revealed that the animals that received CsA monotherapy survived while sustaining more severe hepatic distortion compared with the other study groups treated with SRL. Although the main histopathological characteristic in subjects treated with SRL monotherapy was substantial nodular liver regeneration with almost normal acinar structure, this finding did not reach statistical significance. Whether this beneficial hepatic morphology reflects different properties in the mechanisms of action between SRL and CsA needs further investigation, as the low survival rate in the SRL group does not permit a sound comparison or solid conclusions to be made.
Wu et al. 33 demonstrated that SRL, in pharmacologically effective doses (loading dose of 0.8 mg/kg followed by 0.4 mg/kg), enhanced cell engraftment by downregulating selected inflammatory cytokines in the liver, but profoundly impaired proliferation of transplanted cells necessary for liver repopulation. The present study does not include measurement of these detailed parameters, but our overall findings are similar to the study by Wu et al., 33 protocol) for both the SRL monotherapy and SRL + CsA groups. The influence of SRL can easily explain the differences in the survival rate and histological findings described in present study.
In conclusion, SRL offers no survival advantage when used in a hepatocyte XT model for management of ALF so CsA still maintains a central role in attempts to develop alternative solutions for ALF.
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